Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amivantamab + FOLFIRI
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Amivantamab + FOLFIRI is a combination therapy consisting of amivantamab (a bispecific antibody targeting EGFR and MET) with FOLFIRI chemotherapy (folinic acid, fluorouracil, and irinotecan). This combination has shown promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type metastatic colorectal cancer who have not previously received anti-EGFR therapy. In clinical trials, the combination demonstrated an overall response rate of 49%, median duration of response of 7.4 months, and median progression-free survival of 7.5 months. The safety profile is manageable and consistent with each individual component, without additive toxicity. Common treatment-emergent adverse events include neutropenia, rash, stomatitis, infusion-related reactions, and diarrhea.
- Brand names
- Rybrevant
- Other names
- amivantamab-vmjwFOLFIRIfolinic acid + fluorouracil + irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on amivantamab + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amivantamab + FOLFIRI.